General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
AVIR Pharma Inc.
Indication:
Ulcerative Colitis
Last updated December 17, 2023
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic fibrosis, F508del CFTR mutation, 2 years and older
Last updated December 12, 2023
Breyanzi (lisocabtagene maraleucel)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Last updated December 12, 2023
Status:
Negotiations were not pursued
Manufacturer:
Sandoz Canada Inc.
Indication:
Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)
Last updated December 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes
Last updated November 16, 2023
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Ulcerative Colitis
Last updated November 10, 2023
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Last updated November 3, 2023
Status:
Concluded with an LOI
Manufacturer:
BeiGene, Ltd.
Indication:
Chronic lymphocytic leukemia (CLL) in adult patients
Last updated November 2, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Last updated November 1, 2023
Tecartus (brexucabtagene autoleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory
Last updated October 27, 2023